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Abstract: Hepatic encephalopathy is a temporary decline in mental function that is often
associated with liver disease and/or portal-systemic disease. Hepatic encephalopathy (HE)
symptoms can range from minor cognitive declines to coma and are known to result from excess
10

ammonia accumulations in the blood stream subsequent to liver failure. While HE is known to
result from hepatobiliary disorder, many of the physiological process underlying its development
and progression remain to be elucidated. Recent studies have identified neurological, metabolic,
and microbiome changes implicated in the disease state of HE. In this review, the roles of
traditional pharmaceutical interventions and newly developing understandings of the molecular
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biology underlying hepatic encephalopathy will be explored.

One Sentence Summary: Liver injuries resulting in high blood ammonia concentrations can
cause molecular changes in the brain that lead to the development of HE.
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Abbreviations: HE=hepatic encephalopathy; OHE=overt hepatic encephalopathy; CHE=covert
hepatic encephalopathy; WHC=West Haven Criteria; ISHEN=International Society for Hepatic
Encephalopathy and Nitrogen Metabolism, MELD=Model for End-Stage Liver Disease;
HRQOL=health-related quality of life; ALF=acute liver failure; GDH=glutamate dehydrogenase;
GS=glutamine synthetase; MRI=magnetic resonance imaging; NMDA=N-metil-D-Aspartate;
AMPA= α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; cGMP=cyclic guanosine
monophosphate
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Introduction
Hepatic encephalopathy (herein abbreviated as HE) is a neurological condition resulting
from liver failure. Frequently appearing in individuals with cirrhotic liver disease, termed type C
HE, its onset typically starts gradually and can lead to severe impairment, including coma. Type
5

A HE is resultant of acute liver injury or failure, as in the case of individuals who suddenly
experience chemotoxicity of the liver or physical injury. Type B HE is experienced in the
absence of a liver injury, and rather as a result of portal system shunting. This review will
expand primarily upon type C HE, though the other types of hepatic encephalopathy will also be
implicated. Overt hepatic encephalopathy is estimated to occur in between 30 to 40% of
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individuals who have cirrhotic liver disease (17). Presence of HE in the cirrhotic patient is
related to poor prognosis and may reduce survival when liver transplantation is not performed
(18).

Diagnosis
15

Due to the nature of hepatic encephalopathy as a spectrum disorder, a variety of
diagnostic techniques and measurements are implicated in its diagnosis and treatment. The first
diagnostic criterion is the presence of liver disease. This may be confirmed by imaging, liver
function testing, or biopsy. Certain physical indicators may also align with the diagnosis of HE,
namely asterixis of the arms upon outward stretching with the hands bent upward at the wrist,
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rigidity, tremors, hyperreflexia, or a positive Babinski’s sign in adults (11). Though the causes of
HE vary, the covert and over symptoms are largely uniform between HE types. Overt symptoms
of HE include changes in consciousness, personality, disorientation, and coma. HE can also
present much more subtly, at the onset of chronic disease. This phenomenon is called covert HE
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and may include minimally noticeable symptoms. Diagnosis of minimal covert HE requires
psychometric testing, whereas over HE does not usually require testing to diagnose (2).
Type

Association

Example(s)

A

Acute liver failure without
underlying liver disease

Acute liver failure due to NSAID overdose

B

Portal-systemic bypass without
underlying liver disease

Adverse effects resulting from transjugular
intrahepatic portosystemic shunt procedure (TIPS)

C

Chronic liver disease and/or
cirrhosis

Alcoholic liver cirrhosis, untreated hepatitis, nonalcoholic fatty liver disease (NAFLD)

Table 1

Classification of the presence and severity of HE is determined using the West Haven
5

Criteria (WHC), whereby HE can be diagnosed on a grading scale from 0 to IV regarding
severity. Of note, the West Haven classification system does not assign a numerical grade to
subclinical (minimal) HE, but does recognize it as existing between grade 0, or absence of HE,
and grade I. Grade I HE is indicated by altered mood, such as feelings of euphoria or anxiety,
decreased attention span, inability to concentrate, altered sleep rhythms, and impaired cognitive
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functioning, such as decreased ability to perform addition or subtraction. Patients with Grade I
HE do not experience changes in orientation. Cognitive impairment and behavioral changes are
largely subjective and are noticed by the patient’s caregivers and/or healthcare provider when
compared to the patient’s baseline mental function. WHC Grade II HE is indicated by decreased
energy or motivation, disorientation for time, noticeable personality changes, and inappropriate
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behavior, as well as physical manifestations including dyspraxia and asterixis. Grade III is
indicated by drowsiness, decreased responsiveness to stimulation, confusion, memory loss,
disorientation of time and space, and inappropriate behavior. Physical symptoms of Grade III
HE include all of the previously mentioned physical symptoms of Grades I and II HE, in addition
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to a positive Babinski’s sign and muscle rigidity. Grade IV HE is the most advanced stage of HE.
Patients with Grade IV HE are comatose and do not respond to any stimuli.
The stages of HE as defined by the West Haven Criteria can be split into two categories:
overt hepatic encephalopathy, and covert hepatic encephalopathy. Covert HE (CHE) includes
5

subclinical HE and WHC Grade I and are labeled as such due to their less clinically obvious
symptoms. Overt HE (OHE) encompasses the group of HE grades that present with physical
symptoms, such as asterixis or tremor. OHE includes WHC Grades II through IV and is thought
to be more easily diagnosed due to the overt nature of symptom presentation in these grades. In
addition to the psychomotor and physical symptoms described above, patients experiencing
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WHC Grades I through III have also been found to experience abnormalities in the brain’s
electrical activity as evidenced by electroencephalography. Findings from
electroencephalographic studies indicate a triphasic wave form in Grades I, II, and III, and a
delta activity in WHC Grade IV patients (11).
Diagnosis of subclinical, or minimal, HE presents a unique challenge for the practitioner,
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as patients with this stage of HE do not show clinical signs of HE (13). Minimal hepatic
encephalopathy (MHE) can be viewed as a precursor to clinical HE, as associated cognitive
dysfunction often precipitates further HE symptom development and disease progression (13).
Cognitive declines associated with MHE can include decreased ability to learn maps or spatial
relationships, inability to perform complex math problems, decreased reaction time, decreased
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attention span. In addition to a decreased health-related quality of life (HRQOL), MHE is
associated with an increased incidence of falls in hospitalized patients (14). Falls present both a
burden to the healthcare system, and a significant risk to patients with liver disease, as injuries
associated with falls may be complicated by impaired coagulation resulting from the liver
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disease itself. Due to their decreased reaction times and spatial awareness, patients with MHE
are also four times more likely to be involved in motor vehicle accidents than drivers without
MHE (15). Because of these known harms associated with MHE, accurate diagnosis is incredibly
important. Healthcare providers may benefit from speaking with family members or other
5

members of a patient’s household to identify any behavior changes which may not be otherwise
obvious, as well as to obtain information regarding the patient’s baseline cognitive and
psychomotor functioning. These interviews should accompany psychometric testing to create a
diagnosis of MHE and an individualized treatment plan which considers the patient’s baseline.
Practitioners may also consider a patient’s driving history as part of the diagnostic process, as
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this history may include concrete and quantifiable examples of MHE symptom manifestation
(16).

Disease Pathogenesis
The complexity of HE results in part from the various physiological stressors caused by
15

liver failure. As a result of the decrease of blood filtration and detoxification by the liver,
metabolic wastes build up in the blood (1). Damage to the liver’s mitochondria and surrounding
vasculature impairs the conversion of ammonia to urea via the urea cycle. In a healthy person,
this process allows for excess ammonia to be excreted via the kidneys as urea; in a patient with
liver disease, this excess ammonia may not be removed, and instead builds up in the

20

bloodstream. Ammonia, which is produced by intestinal bacteria, is the most significantly
implicated neurotoxin in HE. Ammonia has been implicated in hepatic encephalopathy since the
1890’s and has since been a target for medication (3).
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While ammonia is a known key player in HE, the exact processes involved in its
overproduction, retention, and neuroactivity are still only partially known. Arterial ammonia
concentrations are not a reliable diagnostic measure due to each patient’s differing sensitivities
after prolonged exposure, but arterial ammonia concentrations greater than 300 μM are
5

considered to reliably predict cerebral herniation in patients with acute liver failure (19). A
relationship between arterial ammonia concentration has also been discovered, in which
increasing ammonia concentrations correlating to increased intracranial pressures in patients with
acetaminophen-induced acute liver failure (ALF) (20). Ammonia in the brain increases
intracellular osmolarity, furthering disease progression by causing changes in cerebral
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mitochondrial function and neurotransmitter synthesis and activity (21).
While there exist several known ways in which ammonia itself directly impacts the brain,
there are several indirect ways in which ammonia contributes to HE, most notably via its
metabolites. Glutamate dehydrogenase (GDH) and glutamine synthetase (GS) are two known
enzymes that are active in the brain and can remove ammonia. GDH catalyzes the production of
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glutamate from alpha-ketoglutarate in both neurons and astrocytes (22). In this reductive
amination reaction, GDH fixates ammonia to create glutamate, and this has been postulated to be
crucial for neuronal survival (22).
Glutamate produced by GDH is converted to glutamine by GS in a reaction that it
thought to occur almost exclusively in astrocytes (23). The conversion of glutamate to glutamine
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is integral in mediating excess ammonia in the brain, with higher extracellular glutamine
concentrations in the brain causing increased cerebral vascularity and corresponding with higher
intracranial pressure (20). Glutamine created by GS exits the cell via the SNAT5 transporter
(24). Once in the extracellular space, glutamine is taken up by SNAT1 and SNAT2 receptors
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into other neurons, where glutaminase converts it back into glutamate (25). This cycle of
metabolic activity is responsible both for the uptake and neutralization of ammonia in the brain,
as well as indirect effects of hyperammonemia including cerebral edema and neuroinflammation
(26).
5
Intestinal microbiome changes linked to HE
The ammonia that causes many of the symptoms of HE is predominantly created by
gram-negative anaerobic bacteria in the lumen of the intestine. Cirrhotic liver disease disrupts
normal digestive activity in the lower intestinal tract, resulting in an abnormal gut microbiome
10

that is significantly dysregulated (4). This unbalanced microbiome contains fewer lactobacilli
than optimal, and is overrun with Enterobacteriacaea, Archaea, Firmicutes, and Prevotella.
These species were found in 2021 to be specifically implicated in increasing ammonia
production in the gut in patients with HE (4). The presence of ammonia-producing species in the
gut relates to several other processes related to HE, namely inflammation and barrier

15

dysfunction, which allow for greater ammonia diffusion across the intestinal epithelia and into
the bloodstream. Enterobacteriaceae in the gut are closely associated with the cognitive and
inflammatory aspects of HE (5). These bacteria have a unique ability to form biofilms in the
intestinal tract which impair the mucus layer (6). Mucins that form the barrier between intestinal
bacteria and the epithelia compose a critically important defense against microbial movement
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from the lumen into the bloodstream (7). The composition of mucins functions both as a
physical barrier to the overgrowth of pathogenic species and as a food source for commensal
species. In a healthy individual, these commensal species strengthen mucosal layers in the gut
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(8). In the liver disease patient, overpopulation of ammonia-producing bacteria combines with
the disruption of the intestinal mucus barrier to increase blood ammonia concentrations.
While patients with liver disease tend to experience an increase in intestinal bacterial
species which produce ammonia and mucolytic enzymes, these patients also experience drastic
5

decreases in bacteria that may mediate these effects. Decreases in Bacteroidetes species have
been found to accompany decreases in liver function (27), a change which has also been
implicated in the development of obesity and intestinal inflammation in clinical studies (28).
Some evidence suggests that patients with liver cirrhosis also experience a delay in
gastrointestinal mobility, which increases risk of bacterial overgrowth and increases the digestive
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time during which ammonia may be absorbed across the gut mucosa (29).
Along with the effects of mucolytic enzymes and delayed small bowel emptying,
ammonia may also enter the bloodstream as a result of small bowel inflammation. In patients
with significant histories of alcohol consumption this presents a particular concern, as alcohol
promotes the growth of Gram-negative bacteria in the small intestine, resulting in a production of

15

endotoxin and acetaldehyde, which increases permeability of the gut mucosa (30).

Neuronal changes in response to ammonia and its metabolites
The symptoms of hepatic encephalopathy all result from insult to the brain on the
cellular, molecular, and large-scale anatomical levels. High-resolution magnetic resonance
20

imaging (MRI) studies have shown that patients diagnosed with MHE tend to have structural
abnormalities of the cerebral cortex (31). MHE patients with cirrhosis have been further shown
to suffer from decreased gray matter volume, and thinning of the superior temporal cortex and
precuneus cortex when compared with healthy brains (32). These anatomical changes in the
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brain have been likened to changes experienced in Alzheimer disease and schizophrenia. The
potential link between HE and Alzheimer disease goes both ways, as changes in liver function
have also been postulated to be a precipitating factor for the development of Alzheimer disease
(33). While uncommon, severe cases of HE have been documented in which hyperammonemia
5

caused cortical laminar necrosis, the death of cells of the of the cerebral cortex. This
phenomenon is usually associated with strokes but has been implicated in several HE case
studies (34). Damage to this layer of the cerebral cortex is particularly causal to the development
of seizures (35).
The development of cerebral edema in HE has long been attributed to the osmotic effects
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of ammonia (21), but several additional mechanisms by which ammonia can cause increased
intracranial pressure have been discovered more recently (46). Microglia, the brain’s immune
cells, are heavily implicated in the terminal process involved in Grade IV HE. Activation of
microglia does not start until the later stages of disease progression. In fact, microglial activation
is found to happen concurrently with opening of the blood-brain barrier and may thereby be
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associated with cerebral edema (46). This sudden microglial activation constitutes part of an
aggressive immune response in the brain, which is believed to exacerbate disease progression to
coma and subsequently increase mortality (46). In microglial cell cultures, microglial activation
and proliferation can be induced by simulating the microglial membrane NMDA receptor, which
provides a potential molecular mechanism by which hyperactivity of microglia can worsen
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neurodegeneration in correlation with elevated brain glutamate levels (47).
By triggering neuroinflammation through microglial activation, ammonia changes the
activity of GABA-ergic receptors. The neurotransmitter GABA functions to block impulses
between neurons, serving as the brain’s way to decrease stimulation and combat anxiety and
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hyperactivity (48). GABA membrane receptors in the brain are responsible for maintaining
cognition and motor function. Upon exposure to neuroinflammation, GABA-ergic receptors
increase expression of the membrane protein GAT-3, which impairs cognition and motor skills
(10). In rat models, this change was reversible with the administration of sulforaphane. It’s
5

believed that this works by reducing altogether inflammation in the brain, and thereby reducing
microglial activation.

The effects of hyperammonemia on the brain also impact several of the cellular
mechanisms regulating the glutamate-glutamine cycle. As previously mentioned, the production
10

of glutamine from glutamate is largely localized to astrocytes. In cases of acute
hyperammonemia, glutamate transporters 1 and 2 (EATT1, EATTT2) are downregulated,
causing high levels of extracellular glutamate which cannot enter the astrocyte (36). While high
ammonia concentrations in the brain decreases EATT signaling activity, they increase signaling
through the N-metil-D-Aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-
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isoxazolepropionic acid (AMPA) pathways (37).
Stimulation of NMDA receptors in the brain activates the glutamate-nitric oxide-cGMP
pathway, which produces cyclic guanosine monophosphate (cGMP) in response to calcium (39).
cGMP plays and important regulatory role in signal transduction and inflammation and has
shown direct impact on neuroplasticity and learning ability (40). The healthy brain experiences
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regulated NMDA signaling activity, but this balance is disturbed by conditions of
hyperammonemia, which can cause both excessive and insufficient glutamate-nitric oxide-cGMP
activity depending on the duration of ammonia exposure. Overstimulation of the NMDA
receptors has been linked to acute hyperammonemia, which may result from acute liver failure
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(41). A relationship has been demonstrated between increased extracellular cGMP
concentrations and encephalopathic state, with cGMP levels markedly increasing at WHC grades
II and III (38). NMDA receptor activation can occur in response to high ammonia levels in the
brain and blocking these receptors increases survival in rats with liver failure (38). In contrast to
5

acute hyperammonemia, chronic hyperammonemia is marked by an adaptive response in the
brain that attempts to mitigate NMDA receptor hyperactivity. While the NMDA receptors
themselves are still hyperactive in chronic hyperammonemia, their tonic activation ultimately
reduces glutamate-NO-cGMP pathway activity in rat models (42). These differing neuronal
signaling effects resulting from acute and chronic hyperammonemia may provide insight into the
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molecular mechanisms which cause distinct symptoms in patients with acute onset HE seen in
Types A and B, compared to those with Type C HE.
Both AMPA receptors and NMDA receptors are glutamate receptors that participate in
excitatory neurotransmission. While AMPA receptors and NMDA receptors share similarities,
AMPA receptors are distinct in many of their molecular mechanisms. AMPA receptors are
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calcium-permeable, and their activation results in an influx of sodium and potassium ions.
Studies using rat models have shown that chronic hyperammonemia results in increased
membrane expression of the GluR1 subunit of AMPA receptor, but decreased expression of the
GluR2 subunit (43). This effect has been experimentally reversed by the administration of
extracellular cGMP, which restored appropriate membrane expression of AMPA receptors (44).
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AMPA receptors are implicated in spatial learning and memory, and these functions are found to
decline as a result of AMPA receptor abnormalities in HE (43,44) which are also seen in the
development of Alzheimer disease (45).
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The molecular impacts of ammonia on the brain’s structure are incredibly widespread and
range from transient, to temporary, to permanent. The brain’s natural ability to change, called
neuroplasticity, is one of the most heavily contended research areas as of the time of the
publication of this review. The American Psychological Association defines neuroplasticity as
5

the brain’s ability to respond to its surroundings and stimuli to change to benefit the host. While
neuroplasticity remains a poorly understood phenomenon, the effects of lactulose treatment on
improving neuroplasticity in patients with minimal HE has been researched (9). Rats with
minimal hepatic encephalopathy receiving lactulose have been found to have increased
reproduction of brain cells, called neurogenesis (9). The researchers involved with this study
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concluded that lactulose treatment not only reduced ammonia levels in the bloodstream, but also
increased the brain’s neuroplasticity. When combined with the molecular effects of NMDA and
AMPA receptors in patients with HE (40; 43-45), this study provides a basis for further
exploration of neuroplasticity as it relates to HE disease state.

15

Hepatic Encephalopathy treatment methods
Lactulose
While several pharmacological treatments for HE exist, by far the most common
therapies are lactulose and rifaximin. The gold-standard treatment for hepatic encephalopathy,
lactulose (1,4 beta galactoside-fructose) is a synthetic disaccharide made of galactose and
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fructose which cannot be absorbed by the human body. Lactulose was first used to treat HE
symptoms in 1966 and received FDA approval for the treatment of HE in 1977 (49). Since its
inception, the osmotic effects of lactulose in the small intestine have proven significant in
reducing HE symptoms by decreasing the amount of ammonia that enters the bloodstream in the
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gut (50). In its syrup form, lactulose can be administered orally or rectally. Because the human
body cannot digest this disaccharide, lactulose passes through much of the digestive tract
unchanged until it reaches the lumen of the colon, where it causes a host of effects that prevent
ammonia absorption across the intestinal lining and into the bloodstream (51).
5

The intestinal bacteria that produce much of the body’s ammonia are targeted both
directly and indirectly by lactulose’s mechanisms of action. In the large intestine, lactulose is
consumed by these bacteria, which causes an increase in osmolality that decreases the luminal
pH (52). This increased acid content in the colon causes a laxative effect, which both limits the
amount of time that colonic ammonia can diffuse across the intestinal membrane, as well as
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expels excess ammonia from the body. Lactulose also promotes the conversion of ammonia
(NH3) to ammonium (NH4+) by gut bacteria as a response to decreased pH (51). Unlike
ammonia, ammonium cannot readily diffuse across the gut membrane, and is thereby trapped in
the colon until it’s removed via bowel movement (50). Furthermore, lactulose-induced acidic
conditions in the intestinal lumen inhibit the survival of urease-producing bacteria, causing
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changes in the gut microbiome that reduce ammonia production (53).

Rifaximin
The non-absorbable antibiotic rifaximin has been approved by the FDA since 2010 for
use in patients with HE as it limits ammonia-producing bacteria in the small intestine. Rifaximin
20

inhibits bacterial reproduction by preventing chain formation in RNA synthesis, a reproductive
requirement for many bacterial species, which attributes to its broad-spectrum of activity (54).
When administered orally, rifaximin has shown efficacy in treating overgrowths intestinal
overgrowths of gram-positive, gram-negative, aerobic, and anaerobic bacterial species (54).
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Rifaximin has been found to be well tolerated (55) and theoretically less likely result in antibiotic
resistance compared to other oral antibiotics (54), which lend to its utility in treating HE longterm. Developments in our understanding of the mucolytic enzymes associated with certain gut
microbiota may provide a secondary mechanism of action, whereby rifaximin can prevent
5

diffusion of ammonia across the gut membranes by inhibiting enteric bacteria whose enzymatic
activities compromise intestinal mucosa.

Considerations in the development of future HE therapies
While the use of rifaximin and lactulose have shown considerable value in reducing the
10

symptoms of HE by reducing blood ammonia concentrations, these medications fail to treat
many of the other molecular mechanisms confounding HE development and progression. Recent
developments in our understanding of HE pathogenesis have created numerous potential avenues
for treatment, but the development of new therapies may be ethically complex as the alreadyexisting treatments cannot be withheld, which may limit placebo trials of other potential drugs.
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This particularly affects our ability to study the efficacy of lactulose, and may prevent us from
developing alternatives, as the role of lactulose in the treatment of HE has been established for
almost fifty years. The efficacy of lactulose compared to other laxatives has also been called
into question as many of the therapeutic effects of lactulose result from its laxative properties.
This has raised concerns about the efficacy of lactulose compared to other laxatives and caused
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speculation that other laxatives may have similar or better therapeutic effects (56).
In addition to concerns about the efficacy of lactulose, studies have elucidated potential
issues regarding its implementation. The current standard for lactulose treatment emphasizes a
titration of dose resulting in 3 daily bowel movements (57). but the reasoning for this titration is
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contested as patients may experience more side effects of lactulose at this dose (58).
Furthermore, this titration of dose is not reflective of efficacy as the frequency of bowel
movements is not indicative of cognitive function (58). These questions leave room for further
investigation into lactulose treatment and potential adjuncts or alternatives.
5
Conclusion
The management and treatment of hepatic encephalopathy present unique challenges to
our healthcare systems due to the incredible complexity of mechanisms underlying disease
development and progression alongside liver injury. While WHC grades II-IV HE present with
10

clinically evident symptoms, the covert nature of symptoms in minimal HE and WHC grade I
may convolute diagnosis. Especially in these earlier cases of HE, the formation of a diagnosis
should take into consideration the patient’s self-reported symptoms as well as observations from
the patient’s support persons, if possible, and any supportive documents, such as traffic
infractions, if applicable. Treatment of covert HE has shown promise in preventing progression
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to overt HE (59).
As the disease state of HE progresses, patients experience significant changes in
intestinal microbiome composition and neuronal signaling, which can lead to structural changes
in the brain. Though hyperammonemia resulting from liver failure is known to cause some of
these changes directly, there exist a multitude of other molecular mechanisms which have been
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implicated in HE, many of which interact and with one-another independently of ammonia.
Some of these pathways and their alterations have been discovered in other neurodegenerative
diseases, such as Alzheimer disease and Parkinson’s diseases (60), in which they have been
attributed to causing symptoms similar to those of HE. Most notably, changes in the NMDR and
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AMPA pathways, as well as microglial hyperactivity, have been related to manifestations
including cerebral edema, impaired spatial learning, cognitive decline, and decreased
neuroplasticity. Though much remains to be done in the field of HE, further understanding of
these processes allows for the development of novel therapies and may even provide insight into
5

other neurodegenerative conditions that share these characteristics.
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